Program

Pleanary sessions

• Opening session with keynote
• Intestines and the ECM: a target to treat?
• Fibroblasts vs cancer cells – who is in control?
• Tissue destruction in autoimmunity and chronic inflammation
• Dermatology- a sign of a systemic disease
• Drivers of multi-organ fibrosis
• The epithelium as a barrier in lung fibrosis and cardiovascular disease
• ECM–immune crosstalk and tissue remodeling
• ECM in health and disease
• Keynote: Cellular Therapeutics in Fibrosis: Progress and Prospects
• Keynote: The matrisome project: From proteomic exploration of the extracellular matrix to matritherapies

Break out-sessions

• Fibrosis models from ex vivo systems to animal models
• Next-generation drug discovery in fibrosis and cancer
• Imaging the dynamics of organ fibrosis
• Strategies for fibrosis resolution
• Degradomics and proteomics
• Young investigators, biotech/pharma career paths & entrepreneurship
• From ECM biology to fibroblast-based therapies
• ECM biomarkers, Reasonably Likely Surrogate Endpoints (RLSE), and regulatory considerations
• 3D disease models: integrating matrix biology and mechanics
• Rethinking fibrosis: biology, therapies, and AI
• Weight loss quality
• Endotrophin: When the matrix becomes a signal
• Fibroblast heterogeneity